Genetic susceptibility to PolyI:C-induced IFNα/β-dependent accelerated disease in lupus-prone mice

Genes and Immunity

Volumn 7, Issue 7, 2006, Pages 555-567

  Jorgensen T N ^a   Thurman, J ^a,b   Izui, S ^c   Falta, M T ^a   Metzger, T E ^a   Flannery, S A ^a   Kappler, J ^a,d   Marrack, P ^a,d   Kotzin, B L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; BETA INTERFERON; COMPLEMENT COMPONENT C3; DOUBLE STRANDED DNA ANTIBODY; DOUBLE STRANDED RNA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC SUSCEPTIBILITY; GLOMERULUS CAPILLARY; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN DEPOSITION; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; DISEASE MODELS, ANIMAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOGLOBULIN G; INTERFERON-ALPHA; INTERFERON-BETA; KIDNEY GLOMERULUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MICE; POLY I-C; PROTEINURIA; SIGNAL TRANSDUCTION;

EID: 33750380857     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364329     Document Type: Article

References (56)

1. Kotzin BL, West SG. Systemic lupus erythrematosus. In: Rich R, Shearer WT, Kotzin BL, Schroeder Jr HW (eds). Clinical Immunology. Principles and Practice. Mosby International Limited: Philadelphia, PA, 2001, pp 60.1-60.24.
2. Vyse TJ, Kotzin BL. Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol 1998; 16: 261-292.
3. Wakeland EK, Liu K, Graham RR, Behrens TW. Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001; 15: 397-408.
4. Stohl W, Xu D, Kim KS, Koss MN, Jørgensen T, Deocharan B et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2080-2091.
5. Gubbels MR, Jorgensen TN, Metzger TE, Menze K, Steele H, Flannery SA et al. Effects of MHC and gender on lupus-like autoimmunity in Nba2 congenic mice. J Immunol 2005; 175: 6190-6196.
6. Xie C, Zhou XJ, Liu X, Mohan C. Enhanced susceptibility to end-organ disease in the lupus-facilitating NZW mouse strain. Arthritis Rheum 2003; 48: 1080-1092.
7. Rozzo SJ, Allard JD, Choubey D, Vyse TJ, Izui S, Peltz G et al. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 2001; 15: 435-443.
8. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777-788.
9. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294: 1540-1543.
10. Braun D, Geraldes P, Demengeot J. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003; 20: 15-25.
11. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
12. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
13. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-4503.
14. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-α induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White)F1 but not in BALB/c mice. J Immunol 2005; 174: 2499-2506.
15. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001; 413: 732-738.
16. Clemens M, Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 1997; 17: 503-524.
17. Honda K, Sakaguchi S, Nakajima C, Watanabe A, Yanai H, Matsumoto M et al. Selective contribution of IFN-α/β signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci USA 2003; 100: 10872-10877.
18. Icely PL, Gros P, Bergeron JJ, Devault A, Afar DE, Bell JC. TIK, a novel serine/threonine kinase, is recognized by antibodies directed against phosphotyrosine. J Biol Chem 1991; 266: 16073-16077.
19. Halloran PF, Urmson J, Van der Meide PH, Autenried P. Regulation of MHC expression in vivo. II. IFN-α/β inducers and recombinant IFN-α modulate MHC antigen expression in mouse tissues. J Immunol 1989; 142: 4241-4247.
20. Fan H, Cook JA. Molecular mechanisms of endotoxin tolerance. J Endotox Res 2004; 10: 71-84.
21. Dalpke AH, Lehner MD, Hartung T, Heeg K. Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance. Immunology 2005; 116: 203-212.
22. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20: 1-17.
23. Peng SL, Szabo SJ, Glimcher LH. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci USA 2002; 99: 5545-5550.
24. Finkelman FD, Svetic A, Gresser I, Snapper C, Holmes J, Trotta PP et al. Regulation by interferon α of immunoglobulin isotype selection and lymphokine production in mice. J Exp Med 1991; 174: 1179-1188.
25. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14: 461-470.
26. Martin RM, Brady JL, Lew AM. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 1998; 212: 187-192.
27. Waters ST, McDuffie M, Bagavant H, Deshmukh US, Gaskin F, Jiang C et al. Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J Exp Med 2004; 199: 255-264.
28. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001; 413: 732-738.
29. Smith PL, Lombardi G, Foster GR. Type I interferons and the innate immune response - more than just antiviral cytokines. Mol Immunol 2005; 42: 869-877.
30. Izui S, McConahey PJ, Clark JP, Hang LM, Hara I, Dixon FJ. Retroviral gp70 immune complexes in NZB x NZW F2 mice with murine lupus nephritis. J Exp Med 1981; 154: 517-528.
31. Maruyama N, Furukawa F, Nakai Y, Sasaki Y, Ohta K, Ozaki S et al. Genetic studies of autoimmunity in New Zealand mice. IV. Contribution of NZB and NZW genes to the spontaneous occurrence of retroviral gp70 immune complexes in (NZB x NZW)F1 hybrid and the correlation to renal disease. J Immunol 1983; 130: 740-746.
32. Patole PS, Grone HJ, Segerer S, Ciubar R, Belemezova E, Henger A et al. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005; 16: 1326-1338.
33. Dikopoulos N, Bertoletti A, Kroger A, Hauser H, Schirmbeck R, Reimann J. Type I IFN Negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells. J Immunol 2005; 174: 99-109.
34. Morel L, Tian XH, Croker BP, Wakeland EK. Epistatic modifiers of autoimmunity in a murine model of lupus nephritis. Immunity 1999; 11: 131-139.
35. Bygrave AE, Rose KL, Cortes-Hernandez J, Warren J, Rigby RJ, Cook HT et al. Spontaneous autoimmunity in 129 and C57BL/6 mice-implications for autoimmunity described in gene-targeted mice. PLoS Biol 2004; 2: E243.
36. Moon U, Park S, Oh S, Kim WU, Park SH, Lee SH et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther 2004; 6: R295-R302.
37. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005; 11: 85-89.
38. Zhu J. Cytomegalovirus infection induces expression of 60 kD/Ro antigen on human keratinocytes. Lupus 1995; 4: 396-406.
39. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and systemic lupus erythematosus: A new perspective. J Immunol 2005; 174: 6599-6607.
40. Morel L, Mohan C, Yu Y, Croker BP, Tian N, Deng A et al. Functional dissection of systemic lupus erythematosus using congenic mouse strains. J Immunol 1997; 158: 6019-6028.
41. Sobel ES, Satoh M, Chen Y, Wakeland EK, Morel L. The major murine systemic lupus erythematosus susceptibility locus Sle1 results in abnormal functions of both B and T cells. J Immunol 2002; 169: 2694-2700.
42. Vyse TJ, Rozzo SJ, Drake CG, Izui S, Kotzin BL. Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice. J Immunol 1997; 158: 5566-5574.
43. Vyse TJ, Drake CG, Rozzo SJ, Roper E, Izui S, Kotzin BL. Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice. J Clin Invest 1996; 98: 1762-1772.
44. Cohen PL, Eisenberg RA. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9: 243-269.
45. Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5: 694-697.
46. Choubey D, Kotzin BL. Interferon-inducible p202 in the susceptibility to systemic lupus. Front Biosci 2002, 7: E252-e262.
47. Asefa B, Klarmann KD, Copeland NG, Gilbert DJ, Jenkins NA, Keller JR. The interferon-inducible p200 family of proteins: A perspective on their roles in cell cycle regulation and differentiation. Blood Cells, Molecules, Dis 2004; 32: 155-167.
48. Wandstrat AE, Nguyen C, Limaye N, Chan AY, Subramanian S, Tian XH et al. Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity 2004; 21: 769-780.
49. Bolland S, Ravetch JV. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 2000; 13: 277-285.
50. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 2005; 307: 590-593.
51. Yang YL, Guo L, Xu S, Holland CA, Kitamura T, Hunter K et al. Receptors for polytropic and xenotropic mouse leukaemia viruses encoded by a single gene at Rmc1. Nat Genet 1999; 21: 216-219.
52. Schwarz K, Simons M, Reiser J, Saleem MA, Faul C, Kriz W et al. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001; 108: 1621-1629.
53. Shimizu S, Nakashima H, Masutani K, Inoue Y, Miyake K, Akahoshi M et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/1pr mice. Rheumatology 2004; 43: 1121-1128.
54. Reilly CM, Olgun S, Goodwin D, Gogal Jr RM, Santo A, Romesburg JW et al. Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/1pr mice. Eur J Immunol 2006; 36: 1296-1308.
55. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM et al. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264: 1918-1921.
56. Merino R, Fossati L, Lacour M, Lemoine R, Higaki M, Izui S. H-2-linked control of the Yaa gene-induced acceleration of lupus-like autoimmune disease in BXSB mice. Eur J Immunol 1992; 22: 295-299.